Drug profile · INN
ruxolitinib phosphate
JAKAFI XR
ruxolitinib phosphate (JAKAFI XR) is a tyrosine-protein kinase jak2 inhibitor. Route of administration: topical. Current US regulatory status: approved.
Drug details — ruxolitinib phosphate
- US status
- approved
- Class
- —
- Route
- TOPICAL
- Patents
- 0
- Programs
- 2
- Data quality
- 0.84
Quick answer
ruxolitinib phosphate (JAKAFI XR) is a tyrosine-protein kinase jak2 inhibitor. Route of administration: topical. Current US regulatory status: approved.
Key facts
Mechanism of action
Tyrosine-protein kinase JAK2 inhibitor
Primary target: Tyrosine-protein kinase JAK1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Recent coverage
Lilly’s early JAK data raises myelofibrosis competition question
Eli Lilly reported early positive data for a next-generation JAK inhibitor acquired through Ajax. The readout could position Lilly as a potential future competitor to Incyte’s Jakafi in myelofibrosis.
FDA Approves Incyte's Jakafi XR Extended-Release Tablets for Myelofibrosis and Blood Disorders
Incyte receives FDA approval for once-daily Jakafi XR (ruxolitinib) extended-release tablets for myelofibrosis, polycythemia vera, and GVHD treatment.
FDA Approves Incyte's Jakafi XR Extended-Release Tablets for Myelofibrosis, Polycythemia Vera Treatment
Incyte receives FDA approval for Jakafi XR (ruxolitinib) extended-release tablets, offering improved dosing convenience for rare blood cancer patients.
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is ruxolitinib phosphate?
ruxolitinib phosphate (JAKAFI XR) is a tyrosine-protein kinase jak2 inhibitor. Route of administration: topical. Current US regulatory status: approved.
What is the brand name for ruxolitinib phosphate?
JAKAFI XR is a marketed brand name for ruxolitinib phosphate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ruxolitinib phosphate?
ruxolitinib phosphate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.